Slide 1: Corporate Presentation
Corporate Presentation NASDAQ: CLRB May 2 2025 Confidential. For Internal Use Only |. For fonts to display correctly, make sure Roboto is downloaded & installed
Slide 2: Forward-Looking Statements and Disclaimers
Forward-Looking Statements and Disclaimers This presentation contains forward-looking statements. Such statements are valid only as of today, and we disclaim any obligation to update this information. These statements are only estimates and predictions and are subject to known and unknown risks and
Slide 3: Cellectar: Overview
Cellectar: Overview Discovering and Developing the Next Generation of Phospholipid Drug Conjugates (PDC’s) • Validated PDC platform with the capacity to deliver a broad array of oncology therapeutic modalities including radioisotopes • Post Phase 2 Phospholipid Radioconjugate (PRC), iopofosine I 131
Slide 4: Planned Milestones
Cellectar: Overview Planned Milestones Q1 Q2 Q3 Q3 Q4 Q1 2025 2025 2025 2025 2025 2026 CLR 125: CLR 125: PHASE 1 STUDY PHASE 1 STUDY INTERIM INITIATION OF EXPANSION IOPOFOSINE 1 131: IOPOFOSINE I-131: IOPOFOSINE I-131: CLR 125: PATIENT DATA COHORT AND DOSE COMPARISON FDA EOP2 MEETING EXPECT FDA WM E
Slide 5: Phospholipid Drug Conjugate (PDC) Platform & Pipeline
Phospholipid Drug Conjugate (PDC) Platform & Pipeline
Slide 6: PDC Platform: Lipid Rafts
Phospholipid Drug Conjugate (PDC) Platform: Lipid Rafts The Role of Lipid Rafts as a Universal Target in Cancer Lipid rafts and play an essential role in cancer Lipid Rafts Play an Influential Role in Cancer Enhanced oncogenic signaling • Concentrate and stabilize growth factor receptors Survival an
Slide 7: PDC Platform: Profile
(PDC) Platform: Profile Universal Targeting with Diverse Payloads PDC CONTAINING DESIRED PAYLOAD WITH SPECIFIC TARGETING OF LIPID RAFT ON CANCER INTERCELLULAR DELIVERY AND RELEASE OF PAYLOAD TUMOR-TARGETING PHOSPHOLIPID ETHER CELL MEMBRANE BY TRANSMEMBRANE FLIPPING OF LIPID RAFT DIVERSE PAN-CANCER C
Slide 8: PDC Platform: Therapeutic Modalities
PDC Platform: Therapeutic Modalities Near Term Focus on Radiotherapeutics THERAPUTIC MODALITIES CONJUGATES ONCOLOGY PAYLOADS Radioconjugate • Beta emitter (131I, 177Lu, 90Y, 67Cu, etc.) • Targeted delivery of any radioisotope • Alpha emitter (211At, 225Ac, 223Ra, 213Bi, etc.) Radioconjugate (PRC) •
Slide 9: PDC Platform: Pipeline
PDC Platform: Pipeline Compound Disease State Preclinical Phase 1 Phase 2 Phase 3/Pivotal Waldenström Phase 3 Confirmatory Study – Initiation TBD macroglobulinemia b-cell Malignancies DLBCL, MM & NHL Iopofosine I 131 Iodine-131 β-emitting radioconjugate Pediatric High-grade Glioma Phase 1b Phase 1b
Slide 10: PDC Platform: Utility Provides Competitive Advantage
(PDC) Platform: Utility Provides Competitive Advantage Ability to Use a Broad Range of Radiotherapeutic Emitters Beta Emitting Alpha Emitting Auger Emitting A Radiation Provides Therapeutic Bystander Effect Radiation Confined to Tumor Environment Radiation Confined to Tumor Cell • Enhanced anti-tumo
Slide 11: PDC Platform: Evolving Radiotherapeutic Landscape
PDC Platform: Evolving Radiotherapeutic Landscape Despite Significant R&D Investment Limited Indications under Development TR P Indust r y Landscape: Phase 1 - Mar k et ed Marketed Radiotherapeutic Indications: 3 • 2 Prostate Cancer (mPC) • 1 Neuroendocrine Tumors (GEP-NET) Late-Stage Radiotherapeut
Slide 12: Phospholipid Radioconjugate (PRC) Program: Auger Emitters
Phospholipid Radioconjugate (PRC) Program Auger Emitters
Slide 13: Auger Properties Provide Enhanced Outcomes
Auger Properties Provide Enhanced Outcomes Greater Precision = Better Toxicity Profile Primary Mechanism of Penetrating Power Relative Biologic Composition Cell Death (Emission Distance) Effect 2 protons Double strand 50 – 100um Alpha Particles ~5 2 neutrons DNA breaks (80-100 keV/μm) Single strand
Slide 14: PRC CLR 121125 (CLR 125): Auger Emitter
PRC CLR 121125 (CLR 125): Auger Emitter ( I) 125 Offers Benefits Vs Other Auger Emitters Why I 125? • One of the highest Auger electron emitters γ • 57-day half-life enhances outcomes • No Beta or Gamma emissions observed Existing data set supports entry into Phase 1b/2 clinical study AE = Auger ele
Slide 15: CLR 125: Statistically Significant Activity and Well Tolerated In Vivo
PRC CLR 121125 (CLR 125): Auger Emitter ( I) 125 Observed Statistically Significant Activity and Well Tolerated In Vivo CLR 125 structurally identical to iopofosine I 131; potentially reduced B development risk A CLR 125 tested in MDA-MB-231 triple negative breast cancer • Observed significant tumor
Slide 16: CLR 125: Enhanced Tumor Uptake Due to Half-Life
PRC CLR 121125 (CLR 125): Auger Emitter ( I) 125 Enhanced Tumor Uptake Due to Half-Life CLR 124 CLR 125 CLR 131 110% 100% Brain Brain Breasts Breasts 100% 90% Stomach Stomach Heart 90% Heart 80% Kidneys Kidneys Liver 80% Liver 70% Lungs Lungs Red Marrow 70% Red Marrow 60% Spleen Spleen Testes Volume
Slide 17: Phase 1b Dose Finding Study in Relapsed TNBC
PRC CLR 121125 (CLR 125): Auger Emitter ( I) 125 Phase 1b Dose Finding Study in relapsed Triple Negative Breast Cancer 3 months 6 months 12 months Study Schematic Phase 1 Study Overview Key Inclusion/Exclusion Criteria 2 doses per cycle: 15 patients per arm • Imaging and therapy study • Confirmed TN
Slide 18: Phospholipid Radioconjugate (PRC) Program: Alpha Emitters
Phospholipid Radioconjugate (PRC) Program Alpha Emitters
Slide 19: CLR 225: Tumor Volume Reduction and Survival Benefit in Pancreatic Cancer
PRC CLR 121225 (CLR 225): Alpha Emitter (225Ac) Tumor Volume Reduction and Survival Benefit in Pancreatic Cancer MIA PaCa-2 Time to Progression BxPC-3 Time to Progression 100 100 90 90 80 80 Progression Free (%) Progression Free (%) 70 70 60 60 50 50 40 Control 40 Control 30 100 nCi 30 250 nCi 20 25
Slide 20: CLR 225: Biodistribution in Pancreatic Model
PRC CLR 121225 (CLR 225): Alpha Emitter (225Ac) Biodistribution in Pancreatic Model 40 4 hours 24 hours 72 hours 30 144 hours %ID/g 20 10 0 Brain Bone Muscle Small Large Stomach Pancreas Liver Spleen Kidney Heart Blood Tumor Intestines Intestines High and Prolonged Tumor Uptake; Low Normal Tissue Up
Slide 21: CLR 225: Tumor Volume Reduction in Prostate Cancer
PRC CLR 121225 (CLR 225): Alpha Emitter ( Ac) 225 Tumor Volume Reduction and Survival Benefit in Prostate Cancer • MyC-CaP and TRAMP-C1 prostate MyC-CaP TRAMP-C1 cancer xenograph models dosed after tumors reached 200mm3 • Doses of 200nCi or 500nCi • Dosimetry data showed increased uptake in TRAMP-C1
Slide 22: CLR 225: Phase 1 Clinical Study
PRC CLR 121225 (CLR 225): Alpha Emitter ( Ac) 225 Phase 1 Clinical Study Excellent labeling efficiency with 225Ac Phase 1 study design Imaging and therapy study Simplified reaction process Dose escalation utilizing an accelerated titration design (allows intrapatient dose escalation for more rapid d
Slide 23: Phospholipid Radioconjugate (PRC) Program: Beta Emitter Iopofosine I 131
Phospholipid Radioconjugate (PRC) program Beta Emitter Iopofosine I 131
Slide 24: Iopofosine I 131: CLOVER-WaM Demographics
PRC Iopofosine I 131: CLOVER-WaM Demographics Patient Characteristics Data Cut-off September 30, 2024 Patient Characteristics Patient Characteristics Safety population, n 65 Median Prior Lines of Therapy, n (range) 4 (2-15) Median age, years (range) 70 (50-88) Prior Treatment/Refractory n (%) Sex, n
Slide 25: Iopofosine I 131: CLOVER-WaM Efficacy Data
PRC Iopofosine I 131: CLOVER-WaM Efficacy Data Best Serum IgM Response by Patient Evaluable Efficacy Population (n=55) ORR = 83.6% MRR = 58.2% DCR = 98.2% 100% 75% 50% 25% IgMReduction (%) 0% * * (25%) * * * * (50%) * * * * * * (75%) * * * (100%) * PD SD MR PR CR/ VGPR DOR and PFS ongoing with media
Slide 26: Iopofosine I 131: CLOVER-WaM Safety Data
PRC Iopofosine I 131: CLOVER-WaM Safety Data Observed Cytopenias Consistent with Treatment of Hematologic Malignancies Any grade Grade ≥3 Most common TEAE (>10% patients), n (%)* Most common TEAE (>10% patients), n (%)* n=65 n=65 Hematologic Toxicities Thrombocytopenia 52 (80.0) Thrombocytopenia 55
Slide 27: Iopofosine I 131: Phase 3 Study Design
PRC Iopofosine I 131: Phase 3 Study Design One Study for Full Approval in Waldenstrom’s macroglobulinemia Primary Endpoint 1: Iopofosine I 131 MRR Randomization (accelerated approval) 1:1 Physicians Choice Primary Endpoint 2: (rituximab or rituximab cyclophosphamide PFS (full approval) dexamethasone
Slide 28: Iopofosine I 131: European Medicine Agency
PRC Iopofosine I 131: European Medicine Agency Regulatory - Conditional Approval Pathway Criteria Requirement Iopofosine Data Benefit/Risk Assessment Survival Data Survival data ongoing form CLOVER-WaM Lack of current treatment options or Medical Need Post BTKi WM patients meet definition significan
Slide 29: Iopofosine I 131: U.S. WM Market Opportunity
PRC Iopofosine I 131: U.S. WM Market Opportunity Addressable Patients in a Concentrated Market with High Unmet Need No Established Standard of Care Across Prevalent Patient Population = 26,000 23 All Lines of Therapy 5 ~11,500 ~4,700 ~1000 1st Line 2nd Line 3rd Line 4th Line Relapsed Refractory 3rd
Slide 30: Iopofosine I 131: r/r Multiple Myeloma Best Response
PRC Iopofosine I 131: r/r Multiple Myeloma Best Response Waterfall Plot of All Multiple Myeloma Patients Multiple myeloma cell lines Best Response by Patient (n=64) 80 Patients receiving at least 60mCi <60 mCi TAD 60 32% ORR >60 mCi TAD CLR 1501 96% DCR Quad-class refractory 40 3.3 months mPFS in po
Slide 31: Iopofosine I 131: Broad Clinical Activity Beyond WM
PRC Iopofosine I 131: Broad Clinical Activity Beyond WM Refractory Primary CNS Lymphoma Refractory Diffuse Large B-cell Lymphoma Complete Response 30% ORR with 10% CRR – CR PFS 6.8 years Relapsed Pediatric High-Grade Glioma Recurrent Head & Neck Cancer Refractory Multiple Myeloma Extended PFS (~12 m
Slide 32: Phospholipid Radioconjugate (PRC) Program: Other Emitters
Phospholipid Radioconjugate (PRC) Program Other Emitters: Lead (212Pb) Lutetium (177Lu)
Slide 33: CLR 121212 (CLR 212): Lead (Pb)
PRC CLR 121212 (CLR 212): Lead ( Pb) 212 Efficacious and Well Tolerated 2500 Efficacy Survival Curve 10uCi PLE at 10uCi/10ng 10uCi PLE at 10uCi/100ng Cold PLE 2000 Buffer only Tumor Volume (mm3) 1500 1000 500 0 0 20 40 60 80 100 120 140 160 180 200 PLE PLE PLE DaysDays since since cellcell injection
Slide 34: CLR 121177 (CLR 177): Lutetium: Activity in Breast Cancer
PRC CLR 121177 (CLR 177): Lutetium ( Lu) 177 Activity in Breast Cancer CLR-177Lu CLR-177Lu 1. control: 2. 9.25MBq: 3. 18.5MBq: 4. fractionated 18.5MBq (2 x 9.25): 5. 3 x 9.25MBq • Lutetium and Yttrium – PLEs tested in 4T07 (uptake) & 4T1 (efficacy) breast cancer xenograft model • Tumors achieved 200
Slide 35: CLR 177: Tissue Uptake and Distribution
PRC CLR 121177 (CLR 177): Lutetium ( Lu) 177 Tissue Uptake and Distribution • Uptake and distribution is similar for CLR-177Lu CLR-177Lu and CLR-86Y: tumor uptake CLR-86Y ~18% infused activity/g tissue • Approximately 2Gy/MBq delivered to the tumor with CLR-177Lu • Tumor volume reduction observed in
Slide 36: Financials: Capitalization
Financials Capitalization BIOSCIENCES
Slide 37: Cellectar Biosciences: Financial Summary
Cellectar Biosciences: Financial Summary Cash Position as of December 31, 2024 (millions) $23.3M Capitalization as of December 31, 2024 Common Stock Outstanding 46,079,875 Reserved for Issuance: Convertible Series D Preferred Stock (111.11 shares) 111,111 Convertible Series E-2 Preferred Stock (35.6
Slide 38: Cellectar's Formula for Value Creation
Cellectar’s Formula for Value Creation Strategic Growth and Expansion • Advance into Phase 1 solid tumor studies – CLR 225 initially pursuing pancreatic cancer, ~ r/r global market potential ~$10B – CLR 125 pursuing triple negative breast cancer ~ r/r global market potential ~$11B • Optimize iopofos
Slide 39: Thank You
Thank You
Slide 40: Executive Management Team
Executive Management Team Greater than 95 years combined leadership experience James Caruso Jarrod Longcor Chad Kolean President, CEO and Director Chief Operating Officer Chief Financial Officer Confidential. For Internal Use Only |. For fonts to display correctly, make sure Roboto is downloaded & i
Slide 41: Footnotes
Footnotes 1. Data on file 2. Internal claims analysis for Waldenstrom’s macroglobulinemia (January 2019-October 2023) 3. Putnam Market Sizing 2023 4. Putnam Quantitative Research 1Q 2023 (n=102 MDs); Putnam Analysis and WM Advisory Boards 5. Komodo Claims Data 6. Real-world data - large community on